Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Tax Provisions (2023 - 2025)

Historic Tax Provisions for Tg Therapeutics (TGTX) over the last 3 years, with Q3 2025 value amounting to -$365.0 million.

  • Tg Therapeutics' Tax Provisions fell 9135000.0% to -$365.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$359.7 million, marking a year-over-year decrease of 7336843.18%. This contributed to the annual value of $2.2 million for FY2024, which is 46692.31% up from last year.
  • Tg Therapeutics' Tax Provisions amounted to -$365.0 million in Q3 2025, which was down 9135000.0% from $2.7 million recorded in Q2 2025.
  • Tg Therapeutics' 5-year Tax Provisions high stood at $2.7 million for Q2 2025, and its period low was -$365.0 million during Q3 2025.
  • Over the past 3 years, Tg Therapeutics' median Tax Provisions value was $395000.0 (recorded in 2023), while the average stood at -$44.9 million.
  • Examining YoY changes over the last 5 years, Tg Therapeutics' Tax Provisions showed a top increase of 130689.66% in 2025 and a maximum decrease of 9135000.0% in 2025.
  • Over the past 3 years, Tg Therapeutics' Tax Provisions (Quarter) stood at $390000.0 in 2023, then skyrocketed by 441.28% to $2.1 million in 2024, then plummeted by 17390.38% to -$365.0 million in 2025.
  • Its Tax Provisions stands at -$365.0 million for Q3 2025, versus $2.7 million for Q2 2025 and $408000.0 for Q1 2025.